Modra

Eric van der Putten - Chief Executive Officer

 

Eric van der Putten is partner at Aglaia Biomedical Ventures, a venture capital firm with a 100% focus on oncology therapeutics and diagnostics.  

He has 30 years of clinical research experience and started his career in 1983 as Head Trial Department of the Comprehensive Cancer Center Amsterdam. Between 1990 and 2000, he held several positions at companies specialized in electronic data collection systems for clinical research, as well as market research for the pharmaceutical industry.

In 2000 Eric joined NDDO Oncology, a spin-off company of the EORTC, where he was COO and CEO. After the acquisition of NDDO Oncology by INC Research in 2005, he became Vice President Oncology for Europe. Eric is one of the co-founders of SMS-oncology, a specialized oncology CRO established in 2007.

 

 

Jan Schellens, MD, PhD - Chief Medical Officer

 

Jan Schellens is co-founder of Modra Pharmaceuticals and is responsible for medical and clinical management. He is medical oncologist, clinical pharmacologist, head of the Department of Clinical Pharmacology (GCP-licensed) of the NKI-AvL, and Professor of Clinical Pharmacology at Utrecht University in the Netherlands.

Jan Schellens has authored more than 750 scientific publications. He has more than 20 years of experience in clinical drug research and over 15 years of experience in drug regulation as member of the Dutch Medicines Evaluation Board (CBG-MEB). He was member of the Scientific Advisory Group Oncology to the European Medicines Agency for 12 years, and was Chair between 2006 - 2012. Jan is an advisor to many pharmaceutical companies including AstraZeneca, Astex, Merck, Pfizer, Roche, Eisai and Clovis Pharma.
 

 

 

 




News

Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more

Events

No current events
Read more